Stop-Smoking Drugs: Mental Health Risk

Popular Stop-Smoking Drugs to Carry Mental Health Risk Warnings

By Todd Neale, Staff Writer, MedPage Today Published: July 01, 2009

WASHINGTON, July 1 -- The FDA said it will immediately require boxed warnings about the risk of serious neuropsychiatric symptoms on the packaging of two popular smoking cessation drugs, -- varenicline (Chantix) and bupropion (Zyban, Wellbutrin, and generics).

Reports of behavioral changes, depressed mood, agitation, hostility, and suicidal thoughts and behavior associated with use of the drugs have been submitted to the FDA's adverse event reporting system. /.../